朝聚眼科医疗控股有限公司（02219）于2026年5月21日发布公告，披露当日于香港联合交易所场内回购股份的相关信息。此次回购共涉及6.00万股普通股，占公司已发行股本约0.009%。回购价格介乎每股2.64港元至2.71港元，合计耗资159,960港元，折合约16.00万港元。
公告显示，朝聚眼科于2026年5月12日获股东通过购回授权，授权可回购股份总数为70,518,050股。截至目前，基于该授权已回购股份累计为240,000股，占授权获通过当日公司已发行股本约0.034%。本次回购后，公司已发行股本仍维持705,180,500股，暂未持有库藏股份。公司确认，本次回购符合香港联合交易所证券上市规则及相关法例。公告由执行董事兼联席公司秘书张光弟先生签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.